Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985540 | 0.86 | VCAM1 (0.35) | VCAM1ALDH1A1KMT2ATSHRTDP1 | |
| SCHEMBL6731121 | 0.84 | ALOX5 (0.34) | VCAM1NPSR1GPR55 | |
| SCHEMBL5983540 | 0.82 | VCAM1 (0.36) | VCAM1ALDH1A1KMT2ANPSR1GPR55 | |
| SCHEMBL6738995 | 0.79 | MEN1 (0.45) | ALDH1A1KMT2ANPSR1GPR55TSHR | |
| SCHEMBL5984007 | 0.78 | VCAM1 (0.34) | VCAM1ALDH1A1KMT2ATSHRTDP1 | |
| SCHEMBL5984640 | 0.78 | VCAM1 (0.32) | VCAM1NPSR1GPR55 | |
| SCHEMBL5984287 | 0.75 | VCAM1 (0.39) | VCAM1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL5984202 | 0.74 | FNTA (0.42) | VCAM1KMT2ANPSR1GPR55 | |
| SCHEMBL5984722 | 0.73 | VCAM1 (0.41) | VCAM1 | |
| SCHEMBL5983556 | 0.72 | TUBB4A (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | claimed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | claimed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | claimed |
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | RENOVIS, INC. | 2005-09-29 | — | — | US | disclosed |
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6730700-B2 | 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002065993-A2 | USE OF ARYL NITRONE COMPOUNDS IN METHODS FOR TREATING NEUROPATHIC PAIN | CENTAUR PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| US-6342523-B1 | DRUGS AND ANTIINFLAMMATORY AGENTS | CENTAUR PHARMACEUTICALS, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1135367-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Centaur Pharmaceuticals, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032567-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | VCAM1 3354/4885ALDH1A1 219/4885KMT2A 2183/4885 |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | VCAM1 316/4885ALDH1A1 121/4885KMT2A 4043/4885 |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | VCAM1 258/4885ALDH1A1 114/4885KMT2A 3997/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | VCAM1 3588/4885ALDH1A1 200/4885KMT2A 2422/4885 |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | CCL11, TXNRD3, CX3CR1 | VCAM1 198/4885ALDH1A1 1148/4885KMT2A 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.